The PAR-1 antagonist Vorapaxar was studied in two large Phase III randomized, double-blind, placebo-controlled clinical trials: the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) [93] and the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis In Myocardial Infarction (TRA2P) [94]. The gene discussed is F2R; the disease is stroke disorder.